patent/EP-2698167-A3

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2698167-A3

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-568 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-785 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-568 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-785 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565
filingDate	2006-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f4afb0ebf58a487b978efc759295efb
publicationDate	2014-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	EP-2698167-A3
titleOfInvention	Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis
abstract	The present invention relates to a dosage form comprising estriol and glatiramer acetate polymer-1 for use in the treatment of multiple sclerosis (MS), as well as to a kit comprising estriol and glatiramer acetate polymer-1.
priorityDate	2005-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5554601-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03072110-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2001016325-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02085374-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005209208-A1
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448746680 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226457370 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419481798 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128958218 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3081884 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5756

Total number of triples: 44.